Clinical Trial: Primary Sjogren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414667) titled 'Primary Sjogren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)' on May 27, 2025.

Brief Summary: This study aims to evaluate the prognostic value of quantitative anti-Ro52 antibody levels in patients with primary Sjogren's Syndrome. Anti-Ro52 antibodies are frequently detected in this autoimmune disease, but their specific role in disease stratification, systemic involvement, and long-term outcomes remains unclear. Through a prospective cohort analysis, the investigators will investigate the association between anti-Ro52 titers and clinical phenotypes, including extragl...